Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M30,489Revenue $M580Net Margin (%)-117.4Altman Z-Score12.0
Enterprise Value $M30,143EPS $-3.1Operating Margin %-108.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score-1.7Pre-tax Margin (%)-117.0Higher ROA y-yN
Price/Book31.010-y EBITDA Growth Rate %--Quick Ratio4.4Cash flow > EarningsY
Price/Sales49.25-y EBITDA Growth Rate %--Current Ratio4.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-31.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-62.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M242ROIC % (ttm)-126.5Gross Margin Increase y-yY

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXVanguard Health Care Fund 2015-03-31 Reduce-0.08%$107.88 - $134.25
($119.81)
$ 125.084%Reduce 2.80%9,533,911
VRTXGeorge Soros 2015-03-31 Buy 0.07%$107.88 - $134.25
($119.81)
$ 125.084%New holding56,912
VRTXKen Fisher 2015-03-31 Add$107.88 - $134.25
($119.81)
$ 125.084%Add 0.18%4,386
VRTXVanguard Health Care Fund 2014-12-31 Reduce-0.58%$101.1 - $120.78
($112.61)
$ 125.0811%Reduce 16.93%9,808,860
VRTXKen Fisher 2014-09-30 Reduce$84.74 - $113.9
($94.97)
$ 125.0832%Reduce 31.99%4,593
VRTXVanguard Health Care Fund 2014-06-30 Add0.04%$62.44 - $94.68
($70.13)
$ 125.0878%Add 1.54%11,807,500
VRTXGeorge Soros 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 125.0879%Sold Out0
VRTXKen Fisher 2014-06-30 Buy $62.44 - $93.77
($69.73)
$ 125.0879%New holding6,753
VRTXVanguard Health Care Fund 2014-03-31 Add0.13%$67.8 - $85.48
($79.08)
$ 125.0858%Add 5.89%11,628,500
VRTXGeorge Soros 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 125.0858%New holding10,000
VRTXVanguard Health Care Fund 2013-12-31 Add0.88%$60.18 - $77.83
($69.45)
$ 125.0880%Add 54.06%10,981,500
VRTXVanguard Health Care Fund 2013-09-30 Add0.29%$74.53 - $88.51
($79.62)
$ 125.0857%Add 19.00%7,127,997
VRTXVanguard Health Care Fund 2013-06-30 Add1.05%$52.6 - $85.6
($73.64)
$ 125.0870%Add 140.58%5,990,000
VRTXNWQ Managers 2013-06-30 Sold Out -0.09%$52.6 - $85.6
($73.64)
$ 125.0870%Sold Out0
VRTXVanguard Health Care Fund 2013-03-31 Add0.05%$43.65 - $54.97
($48.01)
$ 125.08161%Add 10.97%2,489,800
VRTXNWQ Managers 2013-03-31 Reduce-0.02%$41.9 - $54.97
($47.91)
$ 125.08161%Reduce 23.44%191,032
VRTXGeorge Soros 2012-09-30 Sold Out -0.09%$48.38 - $59.07
($53.5)
$ 125.08134%Sold Out0
VRTXJoel Greenblatt 2012-09-30 Sold Out -0.08%$48.38 - $59.07
($53.5)
$ 125.08134%Sold Out0
VRTXNWQ Managers 2012-06-30 Reduce-0.27%$35.75 - $65.62
($50.92)
$ 125.08146%Reduce 83.86%188,842
VRTXJoel Greenblatt 2012-06-30 Buy 0.08%$35.75 - $65.62
($50.92)
$ 125.08146%New holding20,025
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOGER JOSHUA SDirector 2015-05-20Sell11,700$126.73-1.3view
Arbuckle Stuart AEVP\Chief Commercial Officer 2015-05-15Sell148$123.850.99view
SMITH IAN FEVP & CFO 2015-05-15Sell378$125.62-0.43view
Silva Paul MSVP & Corp Controller 2015-05-15Sell135$123.850.99view
Sachdev AmitEVP, Policy, Access & Value 2015-05-15Sell131$123.850.99view
BOGER JOSHUA SDirector 2015-05-13Sell11,700$127.48-1.88view
BOGER JOSHUA SDirector 2015-05-06Sell11,700$122.791.86view
Silva Paul MSVP & Corp Controller 2015-05-05Sell4,101$123.681.13view
Silva Paul MSVP & Corp Controller 2015-04-30Sell859$124.020.85view
BOGER JOSHUA SDirector 2015-04-29Sell11,700$124.590.39view

Press Releases about VRTX :

    Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
    Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 
    Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
    Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
    Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 05 2014 
    Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
    Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
    WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 

    More From Other Websites
    10 S&P 500 Companies to Have the Most Revenue Growth in 2015 May 20 2015
    How to play weak Q2 earnings season: Analysts May 18 2015
    New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM... May 17 2015
    What You Need To Know In Biotech: An ASCO Disappointment, Big Money In Brains And A New CF Drug May 16 2015
    Vertex Could Give Investors Vertigo May 13 2015
    Vertex to Present at the UBS Healthcare Conference on May 19 May 13 2015
    Vertex to Present at the UBS Healthcare Conference on May 19 May 13 2015
    Gilead: No Big Deals May 13 2015
    Vertex Pharmaceuticals (VRTX) Stock Climbs Following FDA Advisory Panel Aprroval May 13 2015
    Analyst: Patients were key to Vertex panel recommendation May 13 2015
    Vertex Pharmaceuticals' Orkambi Wins FDA Panel Backing - Analyst Blog May 13 2015
    Vertex: 'We Remain Confident in Approval,' JPMorgan Says May 13 2015
    Vertex Shares Rally As FDA Panel Backs Orkambi; HC Wainwright Analyst Offers Thoughts May 13 2015
    Early movers: DAL, PLL, HUM, VZ, KMB, FB & more May 13 2015
    FDA Panel Backs Vertex Cystic-Fibrosis Drug Orkambi May 12 2015
    Tuesday's After-Hours Movers: Vertex Pharmaceuticals, Orexigen Therapeutics And More May 12 2015
    IBD Market Wrap - 05/12/15 May 12 2015
    FDA panel approves Vertex drug May 12 2015
    FDA panel backs Vertex cystic-fibrosis drug Orkambi May 12 2015
    After-hours buzz: American Express, Vertex & more May 12 2015
    Vertex CF Drug Orkambi Wins FDA Advisory Panel Vote May 12 2015
    FDA panel backs Vertex combination pill for cystic fibrosis May 12 2015
    FDA panel backs Vertex combination pill for cystic fibrosis May 12 2015
    FDA panel recommends Vertex's ORKAMBI for approval May 12 2015
    FDA questions benefit of cystic fibrosis drug from Vertex May 08 2015
    Vertex says 1Q sales of cystic fibrosis drug grew 31 percent Apr 29 2015
    Vertex Reports First Quarter 2015 Financial Results Apr 29 2015
    Vertex reports 1Q loss Apr 29 2015
    Vertex to Announce First Quarter 2015 Financial Results on April 29 Apr 09 2015
    Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children... Mar 18 2015
    Vertex to Present at Upcoming Investor Conferences Feb 11 2015
    Vertex reports 4Q loss Jan 28 2015
    Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015 Jan 28 2015
    Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New... Jan 11 2015
    U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic... Dec 29 2014
    David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief... Dec 15 2014
    Vertex to Present at Deutsche Bank BioFEST on December 2 Nov 20 2014
    Foundation sells $3.3B in Vertex drug royalties Nov 19 2014
    Vertex to Present at the Credit Suisse Healthcare Conference on November 11 Oct 30 2014
    Vertex tops Street 3Q forecasts Oct 28 2014
    Vertex Reports Third Quarter 2014 Financial Results Oct 28 2014
    US STOCKS-Wall St rallies, S&P back above 14-day moving average Sep 24 2014
    US STOCKS-Biotech shares drop, Amarin plunges 20 pct Sep 12 2014
    US STOCKS-S&P 500 rebounds with energy shares; Dow dips Sep 11 2014
    US STOCKS-Wall St down slightly, financials help limit losses Sep 11 2014
    Vertex Pharma posts bigger 2Q loss Jul 29 2014
    Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating... Jun 27 2014
    Ahead of the Bell: Vertex soars on study Jun 24 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK